Michael K Schultz PhD is a funded NIH investigator, Chief Science Officer of Perspective Therapeutics and a tenured Associate Professor of Radiology, Pediatrics, Free Radical and Radiation Biology, and Chemistry at the University of Iowa. Dr. Schultz has been involved in peptide-based radiopharmaceutical research and the development of new imaging and therapy agents for cancer for nearly 20 years and has been a Project Leader in the NETs Specialized Program of Research Excellence (SPORE) team at the University of Iowa since 2015.
Graeme J. Stasiuk is a Reader (Associate Professor) in Imaging Chemistry at King’s College London. His research includes the design and synthesis of novel multimodal imaging agents for MRI, PET, and Optical Imaging. These include both small molecules and nanomaterials based on inorganic complexes and semiconducting nanoparticles/quantum dots. The research is focused on tools for image-guided surgery and the development of “smart” theranostic imaging agents capable of monitoring drug delivery/efficacy in cancer and cardiovascular disease. He obtained his MChem (2006) and PhD (2010) degrees from the University of Leicester. Following a year at the CEA in Grenoble, he joined Professor Nick Long’s group at Imperial College, London in 2011 as a PDRA. In 2014 he was appointed as a Lecturer in Molecular Imaging at the University of Hull, and in 2020, he moved his research group to King’s College London.
Samantha Y. A. Terry is a Reader in Radiobiology at King's College London, and has in the past worked as a Postdoctoral researcher at King's College London (radionuclide imaging of multiple myeloma); Roche postdoctoral fellow at the Radboud UMC, the Netherlands (radionuclide imaging of tumour microenvironment and arthritis); Postdoctoral researcher at the University of Oxford (targeted radionuclide therapy and the effect of chromatin density); and a PhD student at the University of St Andrews (how chromosomes are damaged after external beam irradiation). Her research focuses on determining how radionuclides used for therapy affect either the cells they are targeting or off-target cells to determine how they can best use these radionuclides.
